Kymera Therapeutics, Inc. (KYMR) has a MoatMap StockRank of 42/100 based on Quality (36/100), Value (36/100), and Momentum (58/100) factor scores. The current signal is HOLD. Kymera Therapeutics, a biotech company, faces the same challenges as other early-stage pharmaceutical firms. It lacks a direct and powerful macro tailwind from the identified themes, and its speculative nature makes it unsuitable for a high-conviction macro-driven fund without deeper, company-specific intelligence.
Kymera Therapeutics is a clinical-stage biopharmaceutical company developing novel small molecule therapeutics that selectively degrade disease-causing proteins using its proprietary targeted protein degradation platform. Its competitive moat is its specialized DELigase™ platform and expertise in molecular glue degraders, targeting previously 'undruggable' proteins across oncology and immunology. Kymera is a cutting-edge biotechnology firm at the forefront of a promising new drug discovery modality.
| Price | $81.46 |
| Market Cap | $6.7B |
| P/E (Forward) | -18.48 |
| Price/Book | 4.16 |
| Return on Equity | -27.1% |
| Return on Invested Capital | -18.7% |
| Debt/Equity | 5.23 |
| Gross Margin | 0.0% |
| Operating Margin | -244.9% |
| Revenue Growth | 55.5% |
| Free Cash Flow | $-139M |
Kymera Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).